Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. (Q39048347)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 February 2014

Language	Label	Description	Also known as
English	Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.	scientific article published on 17 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

reactive oxygen species

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sylvanie Surget

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Emilie Lemieux-Blanchard

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sophie Maïga

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Géraldine Descamps

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Steven Le Gouill

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Catherine Pellat-Deceunynck

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

17 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

55

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2165-2173

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Bendamustine: rebirth of an old drug

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Bendamustine in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Treatment of multiple myeloma: a comprehensive review

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

The histone methyltransferase MMSET regulates class switch recombination

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

p53 regulates a non-apoptotic death induced by ROS.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.871277

21 January 2018

Identifiers

10.3109/10428194.2013.871277

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24308434%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39048347&oldid=2219153489"